Overview
Dr. Wu is an internal medicine physician and health services researcher. Her main research interest is studying the implementation of precision medicine applications to improve clinical care. She is involved in projects currently looking at a patient-facing family history risk assessment tool, MeTree, which provides individualized risk stratification and clinical decision support recommendations to clinicians and patients. In addition she is also involved in a large scale sequencing program in Singapore looking at the intersection of family health history and genomics to better understand how these data elements can complement one another and create more precise risk predictions. She is a member of NHGRI's IGNITE network as a co-investigator on a multi-site pragmatic clinical trial of the impact of pharmacogenetic testing on management of depression and acute, and chronic pain. She is the implementation science advisor for the VA's Pharmacogenomic Testing for Veterans (PHASER) program, which is working to complete preemptive PGx testing on up to 250,000 Veterans by 2024.
Current Appointments & Affiliations
Adjunct Associate Professor in the Department of Medicine
·
2023 - Present
Medicine, General Internal Medicine,
Medicine
Member of Duke Center for Applied Genomics and Precision Medicine
·
2014 - Present
The Precision Medicine Program,
Medicine
Recent Publications
Trends in and predictors of patient pharmacogenomic test uptake in a national health care system.
Journal Article Genet Med · March 2025 PURPOSE: Better understanding patient uptake of pharmacogenomic (PGx) testing may inform its implementation and maximize the benefits that such testing can confer. This study examined patient and provider factors associated with PGx test ordering in a nati ... Full text Link to item CiteFamily history and cancer risk study (FOREST): A clinical trial assessing electronic patient-directed family history input for identifying patients at risk of hereditary cancer.
Journal Article Contemp Clin Trials · January 2025 BACKGROUND: Hereditary cancer syndromes cause a high lifetime risk of early, aggressive cancers. Early recognition of individuals at risk can allow risk-reducing interventions that improve morbidity and mortality. Family health history applications that ga ... Full text Link to item CiteLarge-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects
Preprint · December 23, 2024 Full text CiteRecent Grants
Building and Deploying a Genomic-Medicine Risk Assessment Model for Diverse Primary Care Populations.
ResearchInvestigator · Awarded by National Institutes of Health · 2018 - 2025Implementation, Adoption, and Utility of Family History in Diverse Care Settings
ResearchInvestigator · Awarded by National Institutes of Health · 2013 - 2019View All Grants
Education, Training & Certifications
University of North Carolina, Chapel Hill, School of Medicine ·
2006
M.D.